HealthQuill Pharma
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating evidence to support abbreviated new drug application approvals.
Drugs Health Pharma

FDA draws up new product guidance for developing generic drugs

HQ Team May 21, 2025: The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating.

Read More
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

Read More
Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and commercialise an experimental cancer drug.
Drugs Health Pharma

Pfizer signs $6 billion licensing deal with China’s 3SBio for cancer drug

HQ Team May 20, 2025: Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.

Read More
The UK and Wellcome Trust will invest £600 million to create a new health data research service to accelerate the discovery of life-saving drugs, improve patient care and make Britain “the best place in the world” for medical research.
Drugs Health Pharma

UK, Wellcome to build £600m health data service, fast-pace clinical trials

HQ Team May 19, 2025: The UK and Wellcome Trust will invest £600 million to create a new health data research service to.

Read More
US President Donald Trump’s plan to raise taxes on private philanthropic foundations will harm charities' efforts to provide education, shelter, and food to the country's poor, experts said.
Drugs Health Pharma

US plan to raise taxes on charities a ‘disastrous’ move: Experts say

HQ Team May 19, 2025: US President Donald Trump’s plan to raise taxes on private philanthropic foundations will harm charities’ efforts to provide.

Read More
The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose Alzheimer’s disease, the first such approval in the country.
Drugs Health Pharma

Simple blood test to detect Alzheimer’s disease gets US regulator’s nod

HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose.

Read More